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Sleep Disturbance, Symptoms, Psychological Distress, and Health-Related Quality
of Life in Pulmonary Arterial Hypertension
Abstract
Background:
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevated pulmonary
pressures that lead to right heart failure and premature mortality. Patients experience multiple symptoms
including dyspnea, fatigue and chest pain, but little is known about sleep disturbance, PAH symptoms,
psychological distress and health-related quality of life (HRQOL) in PAH.
Aim:
The purpose of this study was to describe the occurrence of sleep disturbance and compare PAH
symptoms, psychological distress, and HRQOL across severity of sleep disturbance.
Methods:
One hundred and ninety-one participants completed a socio-demographic and clinical data form, PAH
Symptom Severity Scale, Profile of Mood States (POMS) short form and the Medical Outcomes Short
Form-36 (SF-36). Descriptive statistics were used to describe sleep disturbances; analysis of variance
models were used to quantify differences in PAH symptoms, psychological distress and HRQOL by sleep
disturbance groups.
Results:
The majority of participants (n=162, 85%) were women with a mean age of 53 years. Sixty-five (34%)
reported no sleep disturbance; 54 (28%) mild sleep disturbance; 41 (22%) moderate sleep disturbance;
and 31 (16%) severe sleep disturbance. Those reporting higher sleep disturbance severity reported worse
PAH symptoms, psychological distress, and HRQOL.
Conclusions:
Sleep disturbance is a significant finding in PAH. Increasing levels of sleep disturbance are associated
with worse PAH symptoms, psychological states, and health-related quality of life. Interventions that
decrease sleep disturbances may improve symptoms and HRQOL.
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Abstract
Background: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by
elevated pulmonary pressures that lead to right heart failure and premature mortality. Patients
experience multiple symptoms including dyspnea, fatigue and chest pain, but little is known
about sleep disturbance, PAH symptoms, psychological distress and health-related quality of life
(HRQOL) in PAH.
Aim: To describe the occurrence of sleep disturbance and compare PAH symptoms,
psychological distress and HRQOL across severity of sleep disturbance.
Methods: One-hundred ninety one participants completed a socio-demographic and clinical data
form, PAH Symptom Severity Scale, Profile of Mood States short form (POMS) and the Medical
Outcomes Short From-36 (SF-36). Descriptive statistics were used to describe sleep
disturbances; analysis of variance models were used to quantify differences in PAH symptoms,
psychological distress and HRQOL by sleep disturbance groups.
Results: The majority of participants (n=162, 85%) were women with a mean age of 53 years.
Sixty-five (34%) reported no sleep disturbance; 54 (28%) mild sleep disturbance; 41 (22%)
moderate sleep disturbance; and 31 (16%) severe sleep disturbance. Those with reporting higher
sleep disturbance severity reported worse PAH symptoms, psychological distress and healthrelated quality of life.
Conclusions: Sleep disturbance is a significant finding in PAH. Increasing levels of sleep
disturbance are associated with worse PAH symptoms, psychological states, and health-related
quality of life. Interventions that decrease sleep disturbances may improve symptoms and
HRQOL.
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Introduction
Pulmonary arterial hypertension (PAH), one type of pulmonary hypertension, is a
devastating illness affecting primarily young to middle-aged women. PAH is defined
hemodynamically as a mean pulmonary arterial pressure > 25 mmHg and a pulmonary capillary
wedge pressure < 15 mmHg.(1) Overtime, these elevated pulmonary pressures lead to right heart
failure. The etiology of PAH includes idiopathic, familial, connective tissue disease,
portopulmonary hypertension, sickle cell disease and congenital heart disease. Approximately
80% of those diagnosed with PAH are women. The mean age at diagnosis is 50 years,(2)
although there is typically a delay of 2 years from symptom onset to diagnosis.(3) Estimated
prevalence of PAH is 7.6 to 15 cases per million.(4, 5) Symptoms of PAH include fatigue and
dyspnea on exertion that may be attributed to other cardiopulmonary disorders. Mortality
remains high; 61% at 5 years.(6, 7)
Recent studies show patients with PAH experience multiple symptoms that interfere with
their lives and negatively affect their quality of life.(7-9) Sleep disturbance is increasingly
recognized as a factor interfering with the ability to cope with symptoms and maintain healthrelated quality of life (HRQOL).(10) Only two studies investigating sleep disturbance in
pulmonary hypertension have been conducted and these studies illustrate that sleep disturbances
may be a factor greatly interfering with the HRQOL of these patients.(10, 11) Sleep disturbance
in PAH can be caused by insomnia and restless leg syndrome. Seventy-three percent of patients
(N=40) with pulmonary hypertension had poor sleep quality that was associated with depression,
dyspnea and decreased HRQOL.(10) Fifty percent had insomnia, 26% reported excessive
daytime sleepiness (EDS) and 30% were found to have restless leg syndrome. Prostanoid therapy
was associated with improved HRQOL but not sleep quality.(10) In another study 46% (N=55)

6

of those with pulmonary hypertension had restless leg syndrome.(11) Those with a history of
hypothyroidism and opioid use for leg pain were most likely to have restless leg syndrome.
Limitations of these studies included small sample sizes and inclusion of various etiologies of
pulmonary hypertension, making it difficult to generalize to those with PAH only.
These preliminary studies suggest sleep disturbance is present in pulmonary
hypertension, but the prevalence of sleep disturbance in those with PAH only remains unknown.
Understanding the effects of sleep disturbance in patients with PAH may have implications for
interventions and patient outcomes such as morbidity, psychological distress and HRQOL. The
aims of this study were to:
(1)

describe the occurrence of sleep disturbance and

(2)

compare PAH symptom, psychological distress and HRQOL across severity of
sleep disturbance.
Methods

Study Design
A cross-sectional study design was used.
Sample
The convenience sample included 191 participants recruited from United States PAH
support groups, an on-line Pulmonary Hypertension Association (PHA) discussion board, and at
Northeast United States and international Pulmonary Hypertension conferences. The PHA
sponsors a biennial conference where investigators can recruit and enroll study participants. At a
monthly support meeting the principal investigator (PI) was introduced and allowed to briefly
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discuss the purpose of this study and invite participants to approach the PI after the meeting if
they wished to participate. An advertisement was posted by the PHA website administrator;
participants contacted the PI via email if they were interested in participating. Only those
patients self-reporting PAH who were able to read and speak English were included. Patients
were enrolled over an 18 month period.
Measures
Participants completed the following questionnaires: a socio-demographic and clinical
data form, the PAH Symptom Severity Scale, the Profile of Mood States (POMS) short form the
Medical Outcomes Study Short Form- 36 (SF-36).
Socio-demographic and Clinical Data Form: Socio-demographic and clinical variables were
collected via a tool developed by the research team. Socio-demographic information included
gender, age, ethnicity, education, occupation and employment status. Self-reported clinical
variables included date of PAH diagnosis, PAH etiology, initial symptoms of PAH, oxygen and
medication use. World Health Organization (WHO) functional class(1) was assigned by the PI
(LAM) using assessment data from self-reported symptoms. WHO functional class I includes
those with PAH who do not have symptoms such as shortness of breath (SOB) with exertion.
Those with WHO functional class II have mild SOB with exertion while WHO functional class
III patients have moderate to severe symptoms of SOB with exertion. WHO functional class IV
patients have symptoms at rest.(12)
Sleep Disturbance: Sleep disturbance was measured by a single item on the PAH Symptom
Severity Scale labeled “sleep difficulty”. Sleep difficulty is measured on a 0 to 10 scale with
zero indicating absence of sleep difficulty and 10 representing the worst possible sleep difficulty.
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PAH Symptom Severity Scale: The PAH Symptom Severity Scale is a symptom scale developed
by the research team that contains 17 symptoms: SOB with exertion, SOB lying down, SOB at
rest, awakening at night SOB, fatigue, sleep disturbance, chest pain, abdominal swelling,
swelling of ankles and feet, syncope, palpitations, dizziness, cough, nausea, loss of appetite,
hoarseness, Raynaud’s phenomenon (cold, numbness of extremities). Symptoms were selected
based on the literature,(13-15) input from the research team, experts caring for patients with
PAH and patients with PAH. Symptoms are rated on a 0-10 scale, with zero indicating an
absence of the symptom and 10 indicating “extremely intense”. Participants are asked to rate
their symptoms over the past month. The Cronbach alpha for the scale is typically .90-.91;(7) in
the current study alpha was .90. Validity testing is on-going.
Psychological states The POMS short form comprised 30 items that measure fluctuating mood
states. These items form six subscales anger, anxiety, depression, confusion, fatigue and vigor.
Each item is rated on a 5 point Likert scale, 0 (not at all) to 4 (extremely) for each mood state.
Higher scores indicate more negative moods, except vigor which is reversed scored. Concurrent
validity was established using the modified Hopkins Symptom Distress Scales and Minnesota
Multiphasic Personality Inventory-2.(16) Internal consistency ranges from 0.84 to 0.95.(16, 17)
The Cronbach alpha for the current study was .70.
SF-36 The SF-36 is a widely used instrument that measures generic HRQOL. The SF-36
measures physical and mental health by assessing eight subscales. The subscales (general health,
physical functioning, role physical, pain, fatigue, social functioning, mental health, role
emotional) and each composite summary score (mental and physical) are reported on a scale of
0-100 with higher scores indicating better HRQOL. Validity (18) and reliability have been
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established with Cronbach alpha ranges between .73-.96.(19) The Cronbach alpha for the current
study was .84.
Procedure
This investigation conformed with the principles outlined in the Declaration of
Helsinki.(20) This study was approved by the hospital and University Institutional Review
Boards. Participants were given paper and pencil forms and questionnaires to complete along
with a self-addressed stamped envelope. Participants were given unique identification numbers.
Return of completed surveys was considered consent to participate.
Statistical Analysis
The primary outcome measure of sleep disturbance was assessed using the PAH
Symptom Severity Scale. Participants were categorized into four groups on the basis of selfreported sleep disturbance: no (0) mild (1-3), moderate (4-7), and severe (8-10). These
categories were established using existing literature and investigator input.(21-23) Descriptive
statistics are used to characterize the population to which inferences may be made. Specifically,
means and standard deviations are provided for continuous socio-demographic and clinical
characteristics overall, and by sleep disturbance groups, while frequencies and percents are
provided for categorical variables. Comparisons of continuous and categorical sociodemographic and clinical characteristics across groups are made using one-way Analysis of
Variance (ANOVA) models and chi-square statistics, respectively. Medications are compared
across groups using indicator variables for each specific medication. The total number of PAH
symptoms among the sixteen symptoms examined is compared across sleep disturbance groups
using a one-way ANOVA model and the F statistic, with post-hoc pair-wise comparisons
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accomplished on the basis of Dunnett's tests. Similarly, PAH symptom intensity, as well as
POMS and SF-36 subscales, are described overall and within sleep disturbance groups using
means and standard deviations, and compared using one-way ANOVA models and Dunnett's
pair-wise post-hoc tests. No adjustment was made for multiplicity. All statistical analyses were
accomplished using SPSS version 20.(24) Statistical significance was taken at the 0.05 level.
Results
Of the 191 participants, 126 (66%) reported some level of sleep disturbance, Table 1. For
the sleep disturbance categories, 65 (34%) had no sleep disturbance, 54 (28%) mild, 41 (22%)
moderate, and 31 (16%) severe sleep disturbance. There were significant differences among the
sleep disturbance groups with regards to PAH symptoms, psychological distress and HRQOL.
Table 2 provides estimates (mean + SD) for symptom intensity for 16 PAH symptoms.
The symptoms with the highest mean scores for the total sample were SOB with exertion and
fatigue. All symptoms differed significantly between the no sleep disturbance and the severe
sleep disturbance groups. Syncope did not differ among the groups. Pair-wise post-hoc
differences are also indicated in Table 2. Figure 1 provides a visual display of the distribution
for the total number of symptoms by each sleep disturbance group.
With regards to psychological distress, the sleep disturbance groups differed significantly
on all the POMS subscales (anxiety, depression, anger, vigor, fatigue, confusion) and total score,
with results for pair-wise post-hoc differences displayed in Table 3. Confusion was the only
psychological state that differed between no and moderate sleep disturbance.
Similarly, the sleep disturbance groups differed significantly on all SF-36 subscales and
composite summary scores (Table 4). The role emotional subscale differed only between the no
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disturbance and mild sleep disturbance and the no disturbance and severe sleep disturbance
groups.
Discussion
This study demonstrates that sleep disturbance is common in PAH and associated with
other PAH symptoms, psychological distress and HRQOL. As sleep disturbance severity
increases, so does the occurrence of PAH symptoms and there is greater PAH symptom severity.
The linear increase in symptom distress in relation to increasing sleep disturbance suggests that
sleep disturbance increases with symptom severity, creating an escalating cycle of sleep
disturbance and symptoms severity. Higher WHO functional classes and increased oxygen use
were more common as sleep disturbance severity increased.
In our study those with worse sleep disturbance had higher PAH symptom severity and
psychological distress. This is consistent with the results from a small study of patients with
pulmonary hypertension where sleep quality was associated with symptoms (breathlessness,
mood and energy), depression and dyspnea.(10) In patients with heart failure (HF), depression
and fatigue have been associated with insomnia.(25) Additionally our study expands current
knowledge of PAH symptom severity by the use of a comprehensive symptom profile. These are
new findings that may provide a direction for future intervention. Perhaps screening and treating
symptoms in PAH may improve sleep, but more research is necessary to test this hypothesis.
Psychological distress may be another factor explaining the occurrence of sleep
disturbance. Our study shows that sleep disturbance severity was associated with anger, anxiety,
depression, confusion and fatigue. Other studies have shown that depression is associated with
sleep disturbance in PAH(10) and depression and anxiety have been found to be prevalent in
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patients with PAH.(14, 15, 26) While we do not know if sleep disturbance is the outcome of
patients experiencing exacerbated symptoms and psychological distress, these findings provide
us with possible directions for further investigation. For example, future research could target
optimal symptom control (e.g. SOB), which could improve sleep. Conversely, improving sleep
in the patient with PAH may improve their other symptoms.
Our study showed an association with PAH symptom severity and HRQOL. Similar to
our findings, sleep disturbance is common in HF and impairs HRQOL.(27, 28) Impaired sleep
and EDS affect cognition, physical functioning and treatment adherence in patients with HF.(25,
29-32) Our study showed those with worse self-reported sleep disturbance had poorer physical
functioning. Insomnia symptoms are also associated with increased depression, fatigue, EDS and
functional performance in HF (25) and affects global perceived health in sleep-disordered
breathing.(33) Self-reported sleep quality is also associated with functional performance and
mental health in HF.(34) We found those with PAH who had sleep disturbances reported higher
levels of fatigue and depression.
Those with worse sleep also had lower HRQOL in our study. Physically, those with sleep
disturbance also experienced fatigue and limitations in performing physical activities.
Psychologically, those with sleep disturbance had psychological distress, social disability and
emotional problems. A study of patients with pulmonary hypertension found sleep disturbance
was associated with activity and HRQOL.(10) Those with sleep disturbance had worse physical
functioning and lower mental health HRQOL. Studies have shown that insomnia (25) and sleep
quality (35) are associated with functional performance in HF. More investigation is needed to
determine possible underlying mechanisms of sleep disturbance than influence HRQOL in PAH.
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Sixty percent of our sample reported oxygen use and those patients tended to also have
more sleep disturbance than those not reporting oxygen use Patients with obstructive sleep
apnea and EDS were also found to have impaired HRQOL(36) and nocturnal oxygen
desaturation was associated with HRQOL. In patients with stable HF nocturnal brain (B-type)
natriuretic peptide (BNP) changes were related to the severity of night time hypoxemia but not to
the type of sleep-discorded breathing episodes or arousals. No relationship was found between
BNP and the frequency of sleep-disordered events. Nocturnal, intermittent hypoxemia in HF was
associated with the outflow of cardiac natriuretic peptides from cardiac myocytes, suggesting
that nocturnal hypoxia can increase cardiac wall stress and worsen cardiac function. The severity
of hypoxemia did not correlate with increased BNP levels. Sleep-disordered breathing in patients
with HF may have a negative impact due to hypoxia.(37) Similar to these studies, hypoxemia
may be a contributor to sleep disturbance in PAH but more investigation is needed. We did not
collect data on how patients were using their oxygen therapy (continuous, as needed, or at night
only). There could be an undiagnosed sleep disorder or nocturnal hypoxemia contributing to the
perception of disturbed sleep in PAH, but more investigation is needed to clarify the relationship
between oxygen use and sleep disturbance.
While our study demonstrates the prevalence of sleep disturbance in patients with PAH is
common, the reason for this problem remains unclear. Medications such as beta blockers have
been implicated in sleep problems,(38) but were not associated with sleep disturbance in PAH,
nor were angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor agonists
(ARB) in the current study. This may be due to the relatively few people taking beta blockers,
ACEI and ARB in this study.
Limitations
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This study has several limitations. First, a non-random sample was used for this study.
Self-report instruments can lead to recall bias among participants. The sleep measure was only a
single item measure from the PAH Symptom Severity Scale. Single item measures have been
shown to be valid and reliable in measuring other concepts such as stress, (39) and quality of
life.(40) Sleep quality(41) and sleepiness(42) also have been measured using single items. This
single item gives a broad but vague description of the type of sleep disturbance in PAH. We also
did not measure sleep objectively using polysomnography. PAH has several etiologies, some of
the subgroups have very small sample sizes, so there may be differences in how they experience
symptoms, psychological distress and HRQOL. The Cronbach alpha of the POMS was
borderline in this sample suggesting this may not be the best measure of psychological distress in
PAH. Participants self-reported their PAH status, so we do not have verification of their
diagnostic hemodynamics to verify the PAH diagnosis. Although PAH primarily affects women,
men are underrepresented in this sample. Other clinical variables such as current hemodynamics
were not collected and may play an important role in sleep disturbance.
Conclusions
We have established a link between difficulty sleeping and PAH symptoms,
psychological distress and HRQOL in PAH. Now a follow up study is necessary to define the
nature of the sleep disturbance. This study demonstrates the pervasiveness of sleep disturbance
and the interplay among symptoms, psychological distress and HRQOL in patients with PAH.
As we continue to describe the symptom experience in PAH, the need for comprehensive
symptom assessment is needed in the clinical setting. Assessment of symptoms and sleep
disturbance in PAH and implementation of interventions could improve outcomes important to
patients such as symptom control, functional status and HRQOL. In addition, improvement in
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sleep and other symptoms may have an impact on hospital readmissions, morbidity and mortality
outcomes but further research is needed to explore these issues.
In summary, we have demonstrated that those patients with PAH have sleep disturbance and
those with increased sleep disturbance have worse PAH symptoms, psychological distress and
HRQOL. Future research will need to further define sleep disturbance and underlying
mechanisms along with designing and testing interventions to target sleep and symptoms.
Working to improve sleep and symptoms may have an important impact on HRQOL.

16

Implications for Practice


Sleep disturbance is common in pulmonary arterial hypertension (PAH).



Those with increasing difficulty sleeping have worse PAH symptoms and health-related
quality of life.



Screening for sleep difficulty in PAH is needed and interventions to improve sleep need
to be developed and tested.
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Table 1. Socio-demographic and clinical characteristics for the total sample of adults with Pulmonary Arterial Hypertension and
separated by sleep disturbance category
Mild Sleep
Disturbance
(score 1-3) n=54

Moderate Sleep
Disturbance
(score 4-7) n=41

Severe Sleep
Disturbance
(8-10) n=31

p-value

N=191

No Sleep
Disturbance
n=65

Age (years) Mean + SD

53.2 + 15.1

53.2 + 16.4

54.5 + 15.2

52.7 + 51.2

51.6 + 13.5

.853

Gender: female

162 (85%)

54 (83%)

48 (89%)

32 (78%)

28 (90%)

.386

Ethnicity: Caucasian

168 (88%)

56 (86%)

51 (94%)

35 (85%)

26 (84%)

.357

Marital Status: Married

97 (51%)

26 (43%)

30 (56%)

24 (59%)

17 (55%)

.474

Living with family/friends

141 (74%)

18 (30%)

40 (74%)

35 (85%)

23 (74%)

.161

College graduate

113 (59%)

39 (61%)

36 (67%)

23 (56%)

15 (48%)

.641

Full-time

36 (19%)

13 (22%)

9 (17%)

10 (24%)

4 (13%)

.371

Part-time

21 (11%)

5 (8%)

16 (30%)

6 (15%)

4 (13%)

Retired

43 (23%)

18 (31%)

15 (28%)

6 (15%)

4 (13%)

Disabled

77 (43%)

23 (39%)

21 (39%)

15 (28%)

18 (58%)

Idiopathic

114 (60%)

36 (55%)

32 (59%)

27 (66%)

19 (61%)

Autoimmune

36 (19%)

10 (15%)

12 (22%)

5 (12%)

9 (29%)

Variable (N=191)

Total

Working Status

PAH etiology

24

Congenital heart disease

14 (7%)

6 (9%)

3 (6%)

2 (5%)

3 (10%)

Other

27 (14%)

13 (20%)

7 (13%)

7 (17%)

0 (0%)

WHO Functional Class

.

I

22 (12%)

13 (20%)

7 (13%)

2 (5%)

0

II

36 (19%)

17 (26%)

9 (17%)

7 (17%)

3 (10%)

III

54 (28%)

17 (26%)

12 (22%)

16 (39%)

9 (29%)

IV

79 (41%)

18 (28%)

26 (48%)

16 (30%)

19 (61%)

115 (60%)

29 (49%)

37 (73%)

25 (69%)

24 (77%)

.011

CCB

46 (24%)

14 (24%)

14 (30%)

11 (30%)

7 (24%)

.858

ERA

95 (50%)

37 (62%)

25 (52%)

21 (57%)

12 (41%)

.328

PDE-5

110 (58%)

36 (60%)

34 (71%)

25 (68%)

15 (52%)

.332

Prostanoids

75 (39%)

29 (49%)

20 (42%)

15 (41%)

11 (38%)

.771

Diuretics

117 (61%)

40 (67%)

31 (65%)

23 (62%)

23 (79%)

.473

Digoxin

29 (15%)

8 (13%)

9 (19%)

6 (16%)

6 (21%)

.808

Beta Blockers

25 (13%)

10 (15%)

6 (11%)

6 (15%)

3 (10%)

.828

Oxygen Use

.010

Medications

25

ACEI/ARB

23 (12%)

12 (18%)

7 (13%)

4 (10%)

0 (0%)

WHO= World Health Organization; CCB=Calcium channel blockers; ERA= Endothelin receptor antagonists; PDE-5=
Phosphodiesterase 5-inhibitors; ACEI= angiotensin-converting enzyme inhibitors; ARB= angiotensin receptor blocker

.071
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Figure 1. Pulmonary Arterial Hypertension total number of symptoms by sleep disturbance groups
a

=Post hoc pairwise difference p<.05 between no and mild sleep disturbance
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b

c

= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance

= Post hoc pairwise difference p<.05 between no and severe sleep disturbance

d

= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance
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Table 2 Pulmonary Arterial Hypertension symptom intensity (mean + SD) for the full sample and by sleep disturbance groups
Symptom Intensity
Mean+SD

Total sample
N=191

No Sleep
Disturbance
n=65

Mild Sleep
Disturbance
(score 1-3) n=54

Moderate Sleep
Disturbance
(score 4-7) n=41

Severe Sleep
Disturbance
(score 8-10) n=31

p-value

SOB with exertionb,c,e,f
6.2 + 2.7
5.1 + 2.8
6.1 + 2.7
6.7 + 2.3
8.1 + 2.0
<.001
a,b,c,e,f
Fatigue
5.0 + 2.5
3.5 + 2.4
5.0 + 2.5
5.8 + 1.9
6.9 + 1.7
<.001
Swelling of
2.9 + 3.1
1.6 + 2.5
2.4 + 2.8
4.1 + 3.0
5.0 + 3.1
<.001
b,c.d,e
ankles/feet
Palpitationsc,e
2.9 + 2.6
2.1 + 2.2
2.7 + 2.3
3.0 + 2.4
4.7 + 3.3
<.001
c,e
Raynaud’s phenomenon
2.7 + 3.4
1.5 + 2.6
2.5 + 3.1
3.0 + 3.7
5.3 + 3.7
<.001
Dizzinessb,c,e
2.6 + 2.5
1.6 + 2.0
2.2 + 2.2
3.2 + 2.4
5.0 + 2.6
<.001
b,c,e
Abdominal swelling
2.3 + 3.2
1.0 + 2.2
1.9 + 3.0
3.5 + 3.6
4.1 + 3.6
<.001
c,e
Cough
2.3 + 2.6
1.7 + 2.1
1.9 + 2.2
2.8 + 2.7
3.7 + 3.3
.001
Chest pain/discomfortb,c,e
2.2 + 2.4
1.3 + 1.7
2.0 + 2.1
2.6 + 2.3
3.8 + 3.1
<.001
b,c,e
Loss of appetite
1.9 + 2.5
1.0 + 1.9
1.3 + 1.7
2.4 + 2.3
4.1 + 3.4
<.001
SOB at restc.e,f
1.8 + 2.3
1.3 + 1.9
1.5 + 1.8
1.6 + 1.8
3.6 + 3.2
<.001
c
SOB lying down
1.7 + 2.2
0.7 + 0.9
1.6 + 2.0
1.9 + 2.3
3.2 + 3.0
<.001
c,e
Nausea
1.5 + 2.4
0.7 + 1.6
1.2 + 1.8
1.7 + 2.5
3.2 + 3.5
<.001
Hoarsenessc,e
1.5 + 2.3
1.1 + 2.1
1.0 + 1.6
1.7 + 2.5
3.1 + 2.9
<.001
a,b,c,e
Awaken at night SOB
0.9 + 1,8
0.1 + 0.4
0.7 + 1.4
1.1 + 2.0
2.5 + 2.8
<.001
Syncope
0.5 + 1.5
0.4 + 1.6
0.3 + 1.1
0.3 + 1.1
1.1 + 2.3
.079
Symptoms rated on 0-10 scale; 0 represents absence of the symptom; 10 represents worse possible symptom intensity. SOB=shortness
of breath; Raynaud’s phenomenon= numb, painful hands or feet with cold and stress; p<.05 after correction for significant results for
multiple comparisons:
a

=Post hoc pairwise difference p<.05 between no and mild sleep disturbance
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b

c

= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance

= Post hoc pairwise difference p<.05 between no and severe sleep disturbance

d

= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance

e

= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance

f

= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance
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Table 3 Mood states in Pulmonary Arterial Hypertension (mean + SD) for the full sample and by sleep disturbance groups
POMS

Total sample
N=191

No Sleep
Disturbance
n=65

Anxietyb,c

4.2 + 4.3

2.4 + 2.8

Mild Sleep
Disturbance
(score 1-3)
n=54
4.1 + 4.0

Moderate Sleep
Disturbance
(score 4-7)
n=41
5.4 + 5.1

Severe Sleep
Disturbance
(score 8-10)
n=31
6.4 + 5.0

p-value

Depressionb,c

3.6 + 4.1

2.0+ 2.6

3.8 + 4.3

4.3 + 3.8

5.9 + 5.6

<.001

Angerb,c

3.0 + 3.4

1.9 + 2.2

3.3 +3.6

3.7 + 3.6

4.2 + 4.1

.003

Vigora,b,c

6.4 + 4.5

8.9 + 4.4

6.1 + 4.0

4.5 + 3.9

4.5 + 3.8

<.001

Fatigueb,c,e,f

8.7 + 5.3

6.0 + 4.5

8.1 + 4.5

10.2 + 4.2

13.8 + 5.1

<.001

Confusionb

4.7 + 3.2

3.6 + 2.4

4.8 + 3.0

5.2 + 2.8

6.0 + 4.7

.003

Totala,b,c,e

17.5 + 18.8

7.0 + 12.8

16.9 + 16.5

24.2 + 16.7

31.8 + 22.6

<.001

<.001

POMS=Profile of Mood States; Higher scores indicate worse mood scores, except higher vigor represents increased vigor. Total
scores range from -20-100, each subscale score ranges from 0-20.; p<.05 after correction for significant results for multiple
comparisons:
a

=Post hoc pairwise difference p<.05 between no and mild sleep disturbance

b

= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance
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c

= Post hoc pairwise difference p<.05 between no and severe sleep disturbance

d

= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance

e

= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance

f

= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance
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Table 4. Health Status in Pulmonary Arterial Hypertension (mean + SD) for the full sample and by sleep groups
SF-36
Total sample No Sleep
Mild Sleep
Moderate Sleep Severe Sleep
p-value
Disturbance Disturbance
Disturbance
Disturbance
Subscale Scores
N=191
(score 1-3) n=54 (score 4-7)
(score 8-10)
n=65
n=41
n=31

General Healtha,b,c

37.1 + 21.2

46.1 + 22.8

35.9 + 17.5

31.8 + 19.1

27.3 + 20.2

<.001

Physical functiona,b,c

41.5 + 25.9

52.6 + 27.6

35.7 + 22.8

40.1 + 24.5

30.3 + 20.9

<.001

Role physicala,b,c

36.4 + 40.3

56.5 + 41.8

34.7 + 38.4

22.8 + 34.0

15.3 + 28.6

<.001

Paina,b,c,e

66.3 + 27.5

82.1 + 21.7

63.7 + 24.4

61.1 + 26.0

45.2 + 28.2

<.001

Vitalityb,c,e

41.3 + 22.7

51.3 + 22.6

42.0 + 22.7

34.6 + 18.7

27.7 + 18.2

<.001

Social functiona,b,c

65.5 + 26.4

78.7 + 20.3

63.6 + 24.9

54.3 + 28.2

56.0 + 27.1

<.001

Mental healtha,b,c

71.9 + 19.3

80.9 + 13.2

70.3 + 20.2

65.0 + 20.2

65.1 + 20.5

<.001

Role emotionala,c

67.0 + 41.5

81.5 + 33.3

57.9 + 42.1

65.1 + 44.7

54.8 + 44.4

.003

Mental healtha,b,c

61.5 + 21.0

73.1 + 15.3

58.6 + 21.0

54.8 + 20.0

50.9 + 22.4

<.001

Physical healtha,b,c,e

45.4 + 22.7

59.4 + 22.2

42.4 + 18.2

39.0 + 19.8

29.6 + 18.4

<.001

Composite Summary
scores

Higher scores indicate better health; score range 0-100; p<.05 after correction for significant results for multiple comparisons:
a

=Post hoc pairwise difference p<.05 between no and mild sleep disturbance
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b

c

= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance

= Post hoc pairwise difference p<.05 between no and severe sleep disturbance

d

= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance

e

= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance

f

= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance
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